SE9802549D0 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- SE9802549D0 SE9802549D0 SE9802549A SE9802549A SE9802549D0 SE 9802549 D0 SE9802549 D0 SE 9802549D0 SE 9802549 A SE9802549 A SE 9802549A SE 9802549 A SE9802549 A SE 9802549A SE 9802549 D0 SE9802549 D0 SE 9802549D0
- Authority
- SE
- Sweden
- Prior art keywords
- fluoro
- chloro
- propyl
- proviso
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Priority Applications (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
KR10-2000-7014618A KR100516382B1 (ko) | 1998-07-15 | 1999-07-14 | 퀴놀린 유도체 |
PT99933452T PT1095021E (pt) | 1998-07-15 | 1999-07-14 | Derivados de quinolina |
APAP/P/2001/002041A AP1366A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
CA002336968A CA2336968C (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
TR2001/00087T TR200100087T2 (tr) | 1998-07-15 | 1999-07-14 | Kinolin türevleri |
HU0103224A HU229427B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, process for producing them and pharmaceutical compositions containing them |
NZ508923A NZ508923A (en) | 1998-07-15 | 1999-07-14 | N-phenyl-1-Methyl-2-oxo-quinoline-3-carboxamide derivatives, pharmaceuticals thereof and their use in therapy |
IDW20010331A ID27423A (id) | 1998-07-15 | 1999-07-14 | Turunan kuinolin |
PCT/SE1999/001270 WO2000003991A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
BRPI9912109-3A BR9912109B1 (pt) | 1998-07-15 | 1999-07-14 | compostos derivados de quinolina, composições farmacêuticas, processo para a manufatura de um composto, e, uso de um composto. |
EP99933452A EP1095021B1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
PL345388A PL199783B1 (pl) | 1998-07-15 | 1999-07-14 | Związki pochodne chinolino-3-karboksyamidu, zawierające je kompozycje farmaceutyczne, sposób ich wytwarzania i ich zastosowanie |
ES99933452T ES2205854T3 (es) | 1998-07-15 | 1999-07-14 | Derivados de quinolina. |
CNB998085987A CN1157378C (zh) | 1998-07-15 | 1999-07-14 | 喹啉衍生物 |
DK99933452T DK1095021T3 (da) | 1998-07-15 | 1999-07-14 | Quinolinderivater |
RU2001104342/04A RU2213733C2 (ru) | 1998-07-15 | 1999-07-14 | Производные хинолина, способ их получения (варианты), фармацевтическая композиция и способ лечения с их использованием |
IL14034699A IL140346A0 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
AT99933452T ATE250036T1 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
UA2000127299A UA64791C2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives, a method for the preparation thereof, a pharmaceutical composition and a method for treatment of diseases resulting from pathological inflammation or autoimmunity |
EEP200100010A EE04673B1 (et) | 1998-07-15 | 1999-07-14 | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid |
MEP-574/08A MEP57408A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
DE69911415T DE69911415T2 (de) | 1998-07-15 | 1999-07-14 | Chinolinderivate |
OA00100011A OA11906A (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives. |
YUP-15/01A RS50128B (sr) | 1998-07-15 | 1999-07-14 | Derivati hinolina |
CZ20010094A CZ300229B6 (cs) | 1998-07-15 | 1999-07-14 | Deriváty chinolinu |
JP2000560098A JP4045070B2 (ja) | 1998-07-15 | 1999-07-14 | キノリン誘導体 |
AU49504/99A AU751103B2 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
IL140346A IL140346A (en) | 1998-07-15 | 2000-12-14 | Quinoline derivatives, pharmaceutical preparations containing them and a process for their preparation |
IS5775A IS2208B (is) | 1998-07-15 | 2000-12-18 | Quinoline afleiður |
ZA200007593A ZA200007593B (en) | 1998-07-15 | 2000-12-18 | Quinoline Derivatives. |
NO20010211A NO317601B1 (no) | 1998-07-15 | 2001-01-12 | Kinolinderivater |
HR20010039A HRP20010039B1 (en) | 1998-07-15 | 2001-01-12 | Quinoline derivatives |
HK01104765A HK1035715A1 (en) | 1998-07-15 | 2001-07-10 | Quinoline derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9802549D0 true SE9802549D0 (sv) | 1998-07-15 |
Family
ID=20412093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9802549A SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1095021B1 (sv) |
JP (1) | JP4045070B2 (sv) |
KR (1) | KR100516382B1 (sv) |
CN (1) | CN1157378C (sv) |
AP (1) | AP1366A (sv) |
AT (1) | ATE250036T1 (sv) |
AU (1) | AU751103B2 (sv) |
BR (1) | BR9912109B1 (sv) |
CA (1) | CA2336968C (sv) |
CZ (1) | CZ300229B6 (sv) |
DE (1) | DE69911415T2 (sv) |
DK (1) | DK1095021T3 (sv) |
EE (1) | EE04673B1 (sv) |
ES (1) | ES2205854T3 (sv) |
HK (1) | HK1035715A1 (sv) |
HR (1) | HRP20010039B1 (sv) |
HU (1) | HU229427B1 (sv) |
ID (1) | ID27423A (sv) |
IL (2) | IL140346A0 (sv) |
IS (1) | IS2208B (sv) |
ME (1) | MEP57408A (sv) |
NO (1) | NO317601B1 (sv) |
NZ (1) | NZ508923A (sv) |
OA (1) | OA11906A (sv) |
PL (1) | PL199783B1 (sv) |
PT (1) | PT1095021E (sv) |
RS (1) | RS50128B (sv) |
RU (1) | RU2213733C2 (sv) |
SE (1) | SE9802549D0 (sv) |
TR (1) | TR200100087T2 (sv) |
UA (1) | UA64791C2 (sv) |
WO (1) | WO2000003991A1 (sv) |
ZA (1) | ZA200007593B (sv) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
RS51019B (sr) * | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
US20060100257A1 (en) * | 2002-06-05 | 2006-05-11 | Susumu Muto | Inhibitors against the activation of ap-1 and nfat |
CN100490793C (zh) * | 2002-06-11 | 2009-05-27 | 株式会社医药分子设计研究所 | 神经变性疾病治疗药 |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
EP1937642B1 (en) | 2005-10-19 | 2014-09-10 | Teva Pharmaceutical Industries Ltd | Crystals of laquinimod sodium, and process for the manufacture thereof |
PT2035001E (pt) | 2006-06-12 | 2012-02-06 | Teva Pharma | Preparações de laquinimod estáveis |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
RS53199B (en) | 2007-12-20 | 2014-06-30 | Teva Pharmaceutical Industries Ltd. | STABLE LAKVINIMOD PREPARATIONS |
CA2736091A1 (en) | 2008-09-03 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
SI2542079T1 (sl) | 2010-03-03 | 2014-08-29 | Teva Pharmaceutical Industries Ltd. | Zdravljenje revmatoidnega artritisa s kombinacijo lakvinimoda in metotreksata |
SG183512A1 (en) | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
US8580819B2 (en) | 2010-07-09 | 2013-11-12 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
JP5837934B2 (ja) * | 2010-08-27 | 2015-12-24 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Kcnq2/3調節因子としての置換2−オキソ−および2−チオキソ−ジヒドロキノリン−3−カルボキサミド |
RU2013120556A (ru) * | 2010-10-14 | 2014-11-20 | Иммунар Аб | 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr |
EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用 |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
JP5868839B2 (ja) | 2012-12-27 | 2016-02-24 | 三菱重工業株式会社 | チャー払出管 |
JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
CN106573014A (zh) | 2014-04-29 | 2017-04-19 | 梯瓦制药工业有限公司 | 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
AU2015316824B2 (en) | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
ES2663836T3 (es) | 2014-11-19 | 2018-04-17 | Active Biotech Ab | Carboxamidas de quinolina para su uso en el tratamiento de leucemia |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
WO2018105943A1 (ko) * | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
WO2021175924A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
CN116782902A (zh) | 2020-07-23 | 2023-09-19 | 伊拉兹马斯大学鹿特丹医学中心 | 作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白 |
EP4277628A1 (en) | 2021-01-18 | 2023-11-22 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
WO2022248401A1 (en) | 2021-05-25 | 2022-12-01 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
CA3221689A1 (en) | 2021-07-02 | 2023-01-05 | Hans Wannman | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802549A patent/SE9802549D0/sv unknown
-
1999
- 1999-07-14 OA OA00100011A patent/OA11906A/en unknown
- 1999-07-14 ME MEP-574/08A patent/MEP57408A/xx unknown
- 1999-07-14 AT AT99933452T patent/ATE250036T1/de active
- 1999-07-14 EE EEP200100010A patent/EE04673B1/xx unknown
- 1999-07-14 BR BRPI9912109-3A patent/BR9912109B1/pt not_active IP Right Cessation
- 1999-07-14 RU RU2001104342/04A patent/RU2213733C2/ru not_active IP Right Cessation
- 1999-07-14 EP EP99933452A patent/EP1095021B1/en not_active Expired - Lifetime
- 1999-07-14 TR TR2001/00087T patent/TR200100087T2/xx unknown
- 1999-07-14 PT PT99933452T patent/PT1095021E/pt unknown
- 1999-07-14 UA UA2000127299A patent/UA64791C2/uk unknown
- 1999-07-14 WO PCT/SE1999/001270 patent/WO2000003991A1/en not_active Application Discontinuation
- 1999-07-14 ES ES99933452T patent/ES2205854T3/es not_active Expired - Lifetime
- 1999-07-14 DE DE69911415T patent/DE69911415T2/de not_active Expired - Lifetime
- 1999-07-14 IL IL14034699A patent/IL140346A0/xx active IP Right Grant
- 1999-07-14 AU AU49504/99A patent/AU751103B2/en not_active Ceased
- 1999-07-14 PL PL345388A patent/PL199783B1/pl unknown
- 1999-07-14 NZ NZ508923A patent/NZ508923A/xx not_active IP Right Cessation
- 1999-07-14 CA CA002336968A patent/CA2336968C/en not_active Expired - Fee Related
- 1999-07-14 KR KR10-2000-7014618A patent/KR100516382B1/ko not_active IP Right Cessation
- 1999-07-14 JP JP2000560098A patent/JP4045070B2/ja not_active Expired - Fee Related
- 1999-07-14 ID IDW20010331A patent/ID27423A/id unknown
- 1999-07-14 CN CNB998085987A patent/CN1157378C/zh not_active Expired - Fee Related
- 1999-07-14 DK DK99933452T patent/DK1095021T3/da active
- 1999-07-14 CZ CZ20010094A patent/CZ300229B6/cs not_active IP Right Cessation
- 1999-07-14 AP APAP/P/2001/002041A patent/AP1366A/en active
- 1999-07-14 HU HU0103224A patent/HU229427B1/hu not_active IP Right Cessation
- 1999-07-14 RS YUP-15/01A patent/RS50128B/sr unknown
-
2000
- 2000-12-14 IL IL140346A patent/IL140346A/en not_active IP Right Cessation
- 2000-12-18 ZA ZA200007593A patent/ZA200007593B/xx unknown
- 2000-12-18 IS IS5775A patent/IS2208B/is unknown
-
2001
- 2001-01-12 HR HR20010039A patent/HRP20010039B1/xx not_active IP Right Cessation
- 2001-01-12 NO NO20010211A patent/NO317601B1/no not_active IP Right Cessation
- 2001-07-10 HK HK01104765A patent/HK1035715A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9802549D0 (sv) | Quinoline derivatives | |
SE9801474D0 (sv) | Quinoline Derivatives | |
AP1425A (en) | Quinoline derivatives. | |
TR200000837A2 (tr) | Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler. | |
ATE37179T1 (de) | Dihydropyridazinone. | |
ATE139233T1 (de) | Annelierte thiophen-derivate, ihre herstellung und verwendung | |
NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
CA2205274A1 (en) | Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones | |
BR0213731A (pt) | Compostos de silìcio | |
EA200400219A1 (ru) | Производные хинолина и их использование в качестве противоопухолевых средств | |
ATE216233T1 (de) | Indolditerpen alkaloide | |
EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
SE0401578D0 (sv) | Novel compounds | |
IT1205640B (it) | Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono | |
MXPA04000615A (es) | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. | |
ATE56442T1 (de) | 2,6-piperazin-dion-derivate, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
SE0400440D0 (sv) | Novel Cinnamic Amides | |
DK0660840T3 (da) | Phosphono-substituerede tetrazolderivater. | |
PT1214312E (pt) | Indoles 5-aminoalquilo e 5-aminocarbonilo substituidos | |
MX9601953A (es) | Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona. | |
MX9705144A (es) | Uso de un compuesto de carboestirilo para preparar un inhibidor de la produccion o secrecion del factor de necrosis tumoral alfa. |